MedTrace Logo

High Dose Chemo With Stem Cell Transplant as Treatment for Multiple Sclerosis That Failed Prior Treatment

NCT01679041 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2013-11-25

No results posted yet for this study

Summary

The purpose of this study is to evaluate the toxicity and the effectiveness of high dose chemotherapy with HPC transplant Multiple Sclerosis that has failed at least two lines of therapy

Conditions

Interventions

DRUG

Alemtuzumab

Alemtuzumab 10 mg given IV on day 1 of the 5 day conditional regimen

DRUG

Fludarabine

Fludarabine 25mg/m2 daily given IV on days 1-5 of the 5 day conditioning regimen

DRUG

Cyclophosphamide

Cyclophosphamide is given 3 gm/m2 for mobilization, and then repeated during 5 day conditioning regimen w/ doses of 50mg/kg/day on days 1-4

Sponsors & Collaborators

  • Seah Lim M.D.

    lead INDUSTRY

Principal Investigators

  • Seah Lim, MD · Texas Oncology

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-11-30
Primary Completion
2013-11-30
Completion
2013-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01679041 on ClinicalTrials.gov